Insmed (NASDAQ:INSM) Downgraded to Buy at ValuEngine

ValuEngine cut shares of Insmed (NASDAQ:INSM) from a strong-buy rating to a buy rating in a research note published on Wednesday morning, ValuEngine reports.

Several other analysts also recently commented on the stock. HC Wainwright reaffirmed a buy rating and set a $52.00 price objective (up previously from $43.00) on shares of Insmed in a research report on Tuesday, April 9th. BidaskClub downgraded shares of Vertex Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, July 9th. Finally, Zacks Investment Research downgraded shares of Zynerba Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday, May 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $36.63.

Shares of INSM stock opened at $22.14 on Wednesday. Insmed has a 52 week low of $11.31 and a 52 week high of $33.13. The company has a debt-to-equity ratio of 2.48, a current ratio of 4.82 and a quick ratio of 4.69. The stock’s 50 day moving average is $24.34.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.02). The firm had revenue of $21.90 million for the quarter, compared to the consensus estimate of $19.61 million. On average, sell-side analysts expect that Insmed will post -3.58 earnings per share for the current fiscal year.

In related news, CEO William Lewis sold 400,000 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $26.00, for a total value of $10,400,000.00. Following the transaction, the chief executive officer now directly owns 480,672 shares in the company, valued at approximately $12,497,472. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 12,000 shares of the stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $23.24, for a total value of $278,880.00. Following the completion of the transaction, the insider now owns 36,350 shares in the company, valued at $844,774. The disclosure for this sale can be found here. 4.95% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC lifted its holdings in shares of Insmed by 0.6% in the 1st quarter. FMR LLC now owns 11,630,784 shares of the biopharmaceutical company’s stock worth $338,107,000 after purchasing an additional 67,250 shares in the last quarter. Vivo Capital LLC bought a new position in Insmed during the 1st quarter valued at $34,020,000. Emerald Advisers LLC lifted its stake in Insmed by 52.8% during the 1st quarter. Emerald Advisers LLC now owns 921,527 shares of the biopharmaceutical company’s stock valued at $26,789,000 after acquiring an additional 318,482 shares in the last quarter. Geode Capital Management LLC lifted its stake in Insmed by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 866,489 shares of the biopharmaceutical company’s stock valued at $11,368,000 after acquiring an additional 55,026 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust lifted its stake in Insmed by 64.1% during the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 841,119 shares of the biopharmaceutical company’s stock valued at $24,451,000 after acquiring an additional 328,472 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Recommended Story: What are the Benefits of Index Funds?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.